ESC Premium Access

Modeling lipid-lowering therapy intensification in the real world: how many patients with atherosclerotic cardiovascular disease would need a PCSK9 inhibitor?

Congress Presentation

About the speaker

Professor Christopher Paul Cannon

Brigham and Women's Hospital, Boston (United States of America)
38 presentations
0 follower

6 more presentations in this session

Improvement of LDL-cholesterol goal attainment in high-risk patients in Europe and Middle East between 2008/09 and 2013/14 - Results of DYSIS and DYSIS II CHD

Speaker: Doctor A. Gitt (Ludwigshafen, DE)


Statin use and dose by low-density lipoprotein cholesterol level in U.S. commercially insured patients with type 2 diabetes

Speaker: Doctor R. Rosenson (New York, US)


Do we reach the LDL-c goals in Familial hypercholesterolemiapatients under Eighteen Years Old? SAFEHEART (Spanish Familial Hypercholesterolemia Longitudinal Cohort Study) follow-up study

Speaker: Doctor A. Saltijeral Cerezo (Madrid, ES)


Still high prevalence of persistent lipid abnormalities among patients with ACS or stable CHD despite chronic statin therapy in 2014: results of DYSIS II ACS and CHD

Speaker: Doctor A. Gitt (Ludwigshafen, DE)


Residual atherosclerotic cardiovascular disease risk in statin-treated adults: the multi-ethnic study of atherosclerosis

Speaker: Doctor N. Wong (Irvine, US)


Access the full session

Are we ever going to get to lipid goals?

Speakers: Professor C. Cannon, Doctor A. Gitt, Doctor R. Rosenson, Doctor A. Saltijeral Cerezo, Doctor A. Gitt...

About the event


ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb